newsfilter
← Latest News
PR Newswire·

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...